The role of nitric oxide in Doxorubicin-induced cardiotoxicity: experimental study.
OBJECTIVE
We evaluated the myocardial damage in rats treated with doxorubicin (DOX) alone and in combination with nitric oxide synthase (NOS) inhibitors.


METHODS
Twenty-four male Sprague Dawley rats (12 weeks old, weighing 262±18 g) were randomly assigned into 4 groups (n=6). Group I was the control group. In Group II, rats were treated with intraperitoneal (ip) injections of 3 mg/kg DOX once a week for 5 weeks. In Group III, rats received weekly ip injections of 30 mg/kg L-NAME (nonspecific NOS inhibitor) 30 min before DOX injections for 5 weeks. In Group IV, rats received weekly ip injections of 3 mg/kg L-NIL (inducible NOS inhibitor) 30 min before DOX injections for 5 weeks. Rats were weighed 2 times a week. At the end of 6 weeks, hearts were excised and then fixed for light and electron microscopy evaluation and tissue lipid peroxidation (malondialdehyde). Blood samples were also obtained for measuring plasma lipid peroxidation.


RESULTS
Weight loss was observed in Group II, Group III, and Group IV. Weight loss was statistically significant in the DOX group. Findings of myocardial damage were significantly higher in animals treated with DOX only than in the control group. Histopathological findings of cardiotoxicity in rats treated with DOX in combination with L-NAME and L-NIL were not significantly different compared with the control group. The level of plasma malondialdehyde in the DOX group (9.3±3.4 µmol/L) was higher than those of all other groups.


CONCLUSIONS
Our results showed that DOX cardiotoxicity was significantly decreased when DOX was given with NO synthase inhibitors.
Karadeniz Technical University, School of Medicine, Department of Pediatric Hematology, Trabzon, Turkey.
Ayşenur
A
Bahadır
Ankara Oncology Hospital, Department of Pediatric Oncology, Ankara, Turkey.
Nilgün
N
Kurucu
Karadeniz Technical University, School of Medicine, Department of Pharmacology, Trabzon, Turkey.
Mine
M
Kadıoğlu
Karadeniz Technical University, School of Medicine, Department of Histology, Trabzon, Turkey.
Engin
E
Yenilme
Doxorubicin; Nitric oxide synthase inhibitors; nitric oxide